Management of Myelodysplastic Syndromes in High-Risk Patients - Episode 1

Classification of Myelodysplastic Syndrome

,

Yazan Madanat, M.D and Mikkael A. Sekeres, M.D. discuss considerations in the classification of myelodysplastic syndrome taking into account disease heterogeneity.

Now Viewing
EP. 1: Classification of Myelodysplastic Syndrome
EP. 2: Clinical Considerations in the Diagnosis of MDS
EP. 3: MDS: Risk Assessment Tools
EP. 4: High-Risk MDS: Prognostic and Predictive Factors
EP. 5: Clinical Implications of High-Risk MDS
EP. 6: High-Risk MDS: Clinical Efficacy Data
EP. 7: MDS Treatment-Related Toxicity and AEs
EP. 8: MDS Treatment: Patient Considerations
EP. 9: MDS: Clinical Primary Endpoints
EP. 10: Unmet Needs in MDS
EP. 11: MDS Treatment Selection: Impact of QoL
EP. 12: Future Directions in MDS

Related Content:

Management of Myelodysplastic Syndromes in High-Risk PatientsHematologic Oncology
NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies
OncLive’s October Roundup of Key FDA Approvals in Oncology
The OncFive: Top Oncology Articles for the Week of 10/27